- Vaccines
- Monoclonal Antibodies
- Interferons Alpha & Beta
- Checkpoint Inhibitors
- Interleukins
- Others
Immunotherapy Drugs Market size was valued at USD 216.1 billion in 2023 and is projected to reach USD 395.34 Billion by 2030, growing at a CAGR of 12.4% from 2024 to 2030 due to surge in the prevalence of chronic diseases. According to International Agency for Research on Cancer (IACR) in 2018, 18.1 Mn people are estimated to be suffering from cancer worldwide, which is expected to reach 29.5 Mn by 2040. Moreover, the rising demand and development of monoclonal antibodies (mAbs) and the emergence of biosimilars are the major factors that are driving the growth of the immunotherapy drugs market. Additionally, favorable reimbursement policies and support by the government fuel the growth of the market. However, the High cost of treatment for chronic diseases hinders the growth of the market over the forecast period. The global immunotherapy drugs market is surging owing to strategic collaborations and definitive agreements between the market players to develop and commercialize products in the market.
Immunotherapy Drugs Market Key Developments:
- In March 2018, Inovio collaborated with ApolloBio Corp, and provided exclusive right to develop, manufacture and commercialize VGX-3100, a DNA immunotherapy, in greater China.
- In March 2018, Novartis collaborated with Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute to develop next generation biomaterials systems to deliver immune-oncology therapies.
Global Immunotherapy Drugs Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
12.4%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Immunotherapy Drugs Market Dynamics
Rising adoption of targeted therapies and quick drug approval processes and rising prevalence rate of lifestyle diseases drives the growth of the market for Immunotherapy drugs. Cancer segment is the fastest growing segment by therapy area owing to increasing prevalence of cancer and the preference of immunotherapy as the first line of treatment for cancer. Rising demand for monoclonal antibodies and development of monoclonal antibodies coupled with the emergence of new biosimilars into the market enhances the growth of the market.
North-America Got Significant Share
Immunotherapy Drugs Market Regional analysis
North America accounted for larger revenue share in global immunotherapy drugs market with significant CAGR owing to presence of large number of market players and development and launch of new molecules into the market. Asia Pacific region is expected to be the fastest growing region over the forecast period due to acceptable regulatory scenario in the region and low cost of drug manufacturing attributes to the growth of the market. Europe market is expected to show the significant growth rate over the forecast years.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Global Immunotherapy Drugs Market Segmentation
By Drugs
By Therapy Area
- Autoimmune & Inflammatory Diseases
- Cancer
- Infectious Diseases
- Others
By End User
- Hospitals/Clinics
- Cancer Research Centers
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa (MEA)
Frequently Asked Questions
The immunotherapy drugs market size was valued at USD 216.1 billion in 2023
The immunotherapy drugs market key players are: Pfizer Inc AstraZeneca Johnson & Johnson Novartis International AG GlaxoSmithKline Plc Merck & Co AbbVie Inc Immatics Biotechnologies Amgen Inc. Hoffmann-La Roche Ltd
The immunotherapy drugs market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive Summary |
| 2. Global Immunotherapy Drugs Market Introduction |
| 2.1. Global Immunotherapy Drugs Market Taxonomy |
| 2.2. Global Immunotherapy Drugs Market Definitions |
| 2.2.1. By Type |
| 2.2.2. By Application |
| 2.2.3. By End User |
| 2.2.4. By Region |
| 3. Global Immunotherapy Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Immunotherapy Drugs Market Dynamic Factors - Impact Analysis |
| 3.6. Global Immunotherapy Drugs Market Competition Landscape |
| 4. Global Immunotherapy Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Immunotherapy Drugs Market, By Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1. Checkpoint Inhibitors (CI) |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Monoclonal Antibodies (mAbs) |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Interferons & Interleukins (IFs & ILs) |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. Global Immunotherapy Drugs Market, By Application, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1. Cancer |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Autoimmune & Inflammatory Diseases |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Infectious Diseases |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7. Global Immunotherapy Drugs Market, By End User, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Clinics |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Immunotherapy Drugs Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Immunotherapy Drugs Market - Opportunity Analysis Index, By Type, Application, End User, and Region, 2024 - 2030 |
| 9. North America Immunotherapy Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Checkpoint Inhibitors (CI) |
| 9.1.2. Monoclonal Antibodies (mAbs) |
| 9.1.3. Interferons & Interleukins (IFs & ILs) |
| 9.1.4. Others |
| 9.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Cancer |
| 9.2.2. Autoimmune & Inflammatory Diseases |
| 9.2.3. Infectious Diseasess |
| 9.2.4. Others |
| 9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Hospitals |
| 9.3.2. Clinics |
| 9.3.3. Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. USA |
| 9.4.2. Canada |
| 9.5. North America Immunotherapy Drugs Market - Opportunity Analysis Index, By Type, Application, End User, and Country, 2024 - 2030 |
| 9.6. North America Immunotherapy Drugs Market Dynamics Trends |
| 10. Europe Immunotherapy Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 10.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Checkpoint Inhibitors (CI) |
| 10.1.2. Monoclonal Antibodies (mAbs) |
| 10.1.3. Interferons & Interleukins (IFs & ILs) |
| 10.1.4. Others |
| 10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Cancer |
| 10.2.2. Autoimmune & Inflammatory Diseases |
| 10.2.3. Infectious Diseasess |
| 10.2.4. Others |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Hospitals |
| 10.3.2. Clinics |
| 10.3.3. Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Rest of Europe |
| 10.5. Europe Immunotherapy Drugs Market - Opportunity Analysis Index, By Type, Application, End User, and Country, 2024 - 2030 |
| 10.6. Europe Immunotherapy Drugs Market Dynamics Trends |
| 11. Asia-Pacific Immunotherapy Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 11.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Checkpoint Inhibitors (CI) |
| 11.1.2. Monoclonal Antibodies (mAbs) |
| 11.1.3. Interferons & Interleukins (IFs & ILs) |
| 11.1.4. Others |
| 11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Cancer |
| 11.2.2. Autoimmune & Inflammatory Diseases |
| 11.2.3. Infectious Diseasess |
| 11.2.4. Others |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Hospitals |
| 11.3.2. Clinics |
| 11.3.3. Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. China |
| 11.4.2. India |
| 11.4.3. Japan |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Immunotherapy Drugs Market - Opportunity Analysis Index, By Type, Application, End User, and Country, 2024 - 2030 |
| 11.6. Asia-Pacific Immunotherapy Drugs Market Dynamics Trends |
| 12. Latin America Immunotherapy Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 12.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Checkpoint Inhibitors (CI) |
| 12.1.2. Monoclonal Antibodies (mAbs) |
| 12.1.3. Interferons & Interleukins (IFs & ILs) |
| 12.1.4. Others |
| 12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Cancer |
| 12.2.2. Autoimmune & Inflammatory Diseases |
| 12.2.3. Infectious Diseasess |
| 12.2.4. Others |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Hospitals |
| 12.3.2. Clinics |
| 12.3.3. Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Rest of Latin America |
| 12.5. Latin America Immunotherapy Drugs Market - Opportunity Analysis Index, By Type, Application, End User, and Country, 2024 - 2030 |
| 12.6. Latin America Immunotherapy Drugs Market Dynamics Trends |
| 13. Middle East and Africa Immunotherapy Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 13.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Checkpoint Inhibitors (CI) |
| 13.1.2. Monoclonal Antibodies (mAbs) |
| 13.1.3. Interferons & Interleukins (IFs & ILs) |
| 13.1.4. Others |
| 13.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Cancer |
| 13.2.2. Autoimmune & Inflammatory Diseases |
| 13.2.3. Infectious Diseasess |
| 13.2.4. Others |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Hospitals |
| 13.3.2. Clinics |
| 13.3.3. Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. South Africa |
| 13.4.3. Rest of MEA |
| 13.5. MEA Immunotherapy Drugs Market - Opportunity Analysis Index, By Type, Application, End User, and Country, 2024 - 2030 |
| 13.6. MEA Immunotherapy Drugs Market Dynamics Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Type Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Pfizer Inc |
| 14.2.2. AstraZeneca |
| 14.2.3. Johnson & Johnson |
| 14.2.4. Novartis International AG |
| 14.2.5. GlaxoSmithKline Plc |
| 14.2.6. Merck & Co |
| 14.2.7. AbbVie Inc |
| 14.2.8. Immatics Biotechnologies |
| 14.2.9. Amgen Inc. |
| 14.2.10. F. Hoffmann-La Roche Ltd |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
- Pfizer Inc
- AstraZeneca
- Johnson & Johnson
- Novartis International AG
- GlaxoSmithKline Plc
- Merck & Co
- AbbVie Inc
- Immatics Biotechnologies
- Amgen Inc.
- Hoffmann-La Roche Ltd